The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
The product patent has been already filed under fast track approval
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)